This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix ...

"Anti-CD40L modulates T cell function and has the ... PMID: 38354138 2Gelman, M. Endpoints. "Biogen, UCB detail response rates in Phase 3 lupus trial after surprising Success" Nov. 19, 2024 ...

For Biogen, dapirolizumab pegol is part of a push ... "Our hypothesis is that impacting the CD40L pathway, a central mechanism in immune response, would translate to significant impact on SLE ...

The promise of CD40L blockers is to modulate the immune system rather than suppress it. Traditional immunosuppression drugs work for transplant and autoimmune diseases, but they carry a number of ...

Deep-pocketed investors have adopted a bullish approach towards Biogen BIIB, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Investors with a lot of money to spend have taken a bullish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology ...